This company listing is no longer active
Taisho Pharmaceutical Holdings Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Akira Uehara
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.8yrs |
| CEO ownership | n/a |
| Management average tenure | 9.8yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | JP¥8b |
| Sep 30 2023 | n/a | n/a | JP¥16b |
| Jun 30 2023 | n/a | n/a | JP¥18b |
| Mar 31 2023 | n/a | n/a | JP¥19b |
| Dec 31 2022 | n/a | n/a | JP¥25b |
| Sep 30 2022 | n/a | n/a | JP¥21b |
| Jun 30 2022 | n/a | n/a | JP¥18b |
| Mar 31 2022 | JP¥113m | JP¥102m | JP¥13b |
| Dec 31 2021 | n/a | n/a | JP¥8b |
| Sep 30 2021 | n/a | n/a | JP¥5b |
| Jun 30 2021 | n/a | n/a | JP¥8b |
| Mar 31 2021 | JP¥119m | JP¥100m | JP¥13b |
| Dec 31 2020 | n/a | n/a | JP¥17b |
| Sep 30 2020 | n/a | n/a | JP¥17b |
| Jun 30 2020 | n/a | n/a | JP¥16b |
| Mar 31 2020 | JP¥111m | JP¥97m | JP¥21b |
| Dec 31 2019 | n/a | n/a | JP¥15b |
| Sep 30 2019 | n/a | n/a | JP¥21b |
| Jun 30 2019 | n/a | n/a | JP¥46b |
| Mar 31 2019 | JP¥116m | JP¥94m | JP¥49b |
Compensation vs Market: Insufficient data to establish whether Akira's total compensation is reasonable compared to companies of similar size in the JP market.
Compensation vs Earnings: Akira's compensation has been consistent with company performance over the past year.
CEO
Akira Uehara (82 yo)
10.8yrs
Tenure
JP¥113,000,000
Compensation
Mr. Akira Uehara has been the Chief Executive Officer at Taisho Pharmaceutical Holdings Co., Ltd since July2013. Mr. Uehara served as Chairman of Taisho Pharmaceutical Co., Ltd until December 30, 2015 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Representative Director | 10.8yrs | JP¥113.00m | no data | |
| Executive VP & Director | 8.8yrs | JP¥123.00m | 0% ¥ 0 | |
| General Manager of Corporate Communications | no data | no data | no data | |
| MD & Executive Director | 12.5yrs | JP¥105.00m | 0% ¥ 0 | |
| Executive Director | no data | no data | 0% ¥ 0 | |
| Executive VP & Director | 2.8yrs | no data | 0% ¥ 0 |
9.8yrs
Average Tenure
Experienced Management: 4581's management team is seasoned and experienced (9.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Representative Director | no data | JP¥113.00m | no data | |
| Executive VP & Director | 16.8yrs | JP¥123.00m | 0% ¥ 0 | |
| MD & Executive Director | 10.8yrs | JP¥105.00m | 0% ¥ 0 | |
| Executive Director | 8.8yrs | no data | 0% ¥ 0 | |
| Executive VP & Director | 2.8yrs | no data | 0% ¥ 0 | |
| Audit & Supervisory Board Member | 3.8yrs | no data | 0% ¥ 0 | |
| Audit & Supervisory Board Member | 5.3yrs | no data | 0% ¥ 0 | |
| Outside Audit & Supervisory Board Member | 8.8yrs | no data | no data | |
| Independent Outside Director | 5.3yrs | no data | 0% ¥ 0 | |
| Director | 3.3yrs | no data | 0% ¥ 0 | |
| Audit & Supervisory Board Member | 2.8yrs | no data | 0% ¥ 0 |
5.3yrs
Average Tenure
74yo
Average Age
Experienced Board: 4581's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/12 20:24 |
| End of Day Share Price | 2024/04/11 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Taisho Pharmaceutical Holdings Co., Ltd. is covered by 16 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |